Studies related to Liver Damage and Cordyceps

Clinical Application Of Cordyceps Sinensis On Immunosuppressive Therapy In Renal Transplantation

Effect Decrease
Trial Design Double blind
Trial Length 6+ Months
Number of Subjects 167
Sex Both Genders
Age Range 30-44
Notes for this study:
In patients who were going to undergo renal transplants, divided into either a control group given standard immunosuppressive therapy (pulse therapy with methylprednisolone, and cyclophosphamide followed later by mycophenolate mofetil and prednisone) or an experimental group given the aforementioned but with cordyceps (c. sinensis) at 1g three times daily, supplementation was found to confer more benefits than control without cordyceps.

There were reductions in instances of organ damage (liver and kidney; from 18.35% down to 7.53%), serum uric acid, urinary proteins (from 2.25+/-0.58g down to 1.77+/-0.43g), total bilirubin, and serum creatinine; ALT (biomarker for liver damage) among patients without hepatotoxicity did not differ.

Overall survival rates did not differ between groups.